Polaryx Therapeutics, Inc. PLYX Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Polaryx Therapeutics, Inc. 's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Polaryx Therapeutics, Inc. 's business segments — net income loss?
- Polaryx Therapeutics, Inc. (PLYX) reported business segments — net income loss of -$2.54M in Q1 2026.
- How has Polaryx Therapeutics, Inc. 's business segments — net income loss changed year-over-year?
- Polaryx Therapeutics, Inc. 's business segments — net income loss increased by 49.6% year-over-year, from -$5.05M to -$2.54M.
- What does business segments — net income loss mean?
- This metric represents the bottom-line financial performance of the lysosomal storage disorders segment, calculated by subtracting segment-specific operating expenses from any associated revenues. As a pre-revenue or early-stage biotech segment, this figure typically reflects a net loss representing the burn rate of the division. It is a critical indicator of the segment's current profitability status and the capital required to sustain its operations.